ascendis transcon glp-1 program Novo inks deal to develop long-acting GLP-1, other metabolic drugs Ascendis Pharma has granted Novo

Name: ascendis transcon glp-1 program Novo inks deal to develop long-acting GLP-1, other metabolic drugs Ascendis Pharma has granted Novo
Brand: www.allread.ai
SKU: 11111456914
Price: 28.34 USD
Availability: InStock
Rating: 4.3762 (13 reviews)

SKU: 11111456914

4.4

USD28.34 USD52.34

Pay in 4 interest-free payments of $7.08 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 1 - Aug 6

Live Spec

Ascendis Pharma has granted Novo Nordisk an exclusive worldwide license for the TransCon platform to develop and commercialize products for metabolic diseases, including obesity and type 2 diabetes, along with a product specific GLP 1 Weight Loss Drug Market Size, Share Forecast 2026 2034 S 1 A Issue 42: GLP 1 RA Drug Development The Altascientist Novo Nordisk and Ascendis enter $285m partnership for once monthly GLP 1 drug PMLiVE Ascendis Pharma and Novo Nordisk to Develop Treatments for Metabolic and Cardiovascular Diseases American Pharmaceutical Review

Store: www.allread.ai · Domain: www.allread.ai

Description

A study reported that large doses of acetaldehyde, (derived from alcohol) killed 90% of the rats who consumed it